FAPI-74 PET/CT Using Either 18F-AlF or Cold-Kit 68Ga Labeling: Biodistribution, Radiation Dosimetry, and Tumor Delineation in Lung Cancer Patients
Frederik L Giesel, Sebastian Adeberg, Mustafa Syed, Thomas Lindner, Luis David Jiménez-Franco, Eleni Mavriopoulou, Fabian Staudinger, Eric Tonndorf-Martini, Sebastian Regnery, Stefan Rieken, Rami El Shafie, Manuel Röhrich, Paul Flechsig, Andreas Kluge, Annette Altmann, Jürgen Debus, Uwe Haberkorn, Clemens Kratochwil, Frederik L Giesel, Sebastian Adeberg, Mustafa Syed, Thomas Lindner, Luis David Jiménez-Franco, Eleni Mavriopoulou, Fabian Staudinger, Eric Tonndorf-Martini, Sebastian Regnery, Stefan Rieken, Rami El Shafie, Manuel Röhrich, Paul Flechsig, Andreas Kluge, Annette Altmann, Jürgen Debus, Uwe Haberkorn, Clemens Kratochwil
Abstract
68Ga-fibroblast activation protein inhibitors (FAPIs) 2, 4, and 46 have already been proposed as promising PET tracers. However, the short half-life of 68Ga (68 min) creates problems with manufacture and delivery. 18F (half-life, 110 min) labeling would result in a more practical large-scale production, and a cold-kit formulation would improve the spontaneous availability. The NOTA chelator ligand FAPI-74 can be labeled with both 18F-AlF and 68Ga. Here, we describe the in vivo evaluation of 18F-FAPI-74 and a proof of mechanism for 68Ga-FAPI-74 labeled at ambient temperature. Methods: In 10 patients with lung cancer, PET scans were acquired at 10 min, 1 h, and 3 h after administration of 259 ± 26 MBq of 18F-FAPI-74. Physiologic biodistribution and tumor uptake were semiquantitatively evaluated on the basis of SUV at each time point. Absorbed doses were evaluated using OLINDA/EXM, version 1.1, and QDOSE dosimetry software with the dose calculator IDAC-Dose, version 2.1. Identical methods were used to evaluate one examination after injection of 263 MBq of 68Ga-FAPI-74. Results: The highest contrast was achieved in primary tumors, lymph nodes, and distant metastases at 1 h after injection, with an SUVmax of more than 10. The effective dose per a 100-MBq administered activity of 18F-FAPI-74 was 1.4 ± 0.2 mSv, and for 68Ga-FAPI-74 it was 1.6 mSv. Thus, the radiation burden of a diagnostic 18F-FAPI-74 PET scan is even lower than that of PET scans with 18F-FDG and other 18F tracers; 68Ga-FAPI-74 is comparable to other 68Ga ligands. FAPI PET/CT supported target volume definition for guiding radiotherapy. Conclusion: The high contrast and low radiation burden of FAPI-74 PET/CT favor multiple clinical applications. Centralized large-scale production of 18F-FAPI-74 or decentralized cold-kit labeling of 68Ga-FAPI-74 allows flexible routine use.
Keywords: FAPI PET/CT; cancer-associated fibroblasts; cold kit; lung cancer; radiation dosimetry.
© 2021 by the Society of Nuclear Medicine and Molecular Imaging.
Figures
References
- Brennen WN, Isaacs JT, Denmeade SR. Rationale behind targeting fibroblast activation protein-expressing carcinoma-associated fibroblasts as a novel chemotherapeutic strategy. Mol Cancer Ther. 2012;11:257–266.
- Jansen K, Heirbaut L, Cheng JD, et al. . Selective inhibitors of fibroblast activation protein (FAP) with a (4-quinolinoyl)-glycyl-2-cyanopyrrolidine scaffold. ACS Med Chem Lett. 2013;4:491–496.
- Lindner T, Loktev A, Altmann A, et al. . Development of quinoline-based theranostic ligands for the targeting of fibroblast activation protein. J Nucl Med. 2018;59:1415–1422.
- Loktev A, Lindner T, Mier W, et al. . A tumor-imaging method targeting cancer-associated fibroblasts. J Nucl Med. 2018;59:1423–1429.
- Giesel FL, Kratochwil C, Lindner T, et al. . 68Ga-FAPI PET/CT: biodistribution and preliminary dosimetry estimate of 2 DOTA-containing FAP-targeting agents in patients with various cancers. J Nucl Med. 2019;60:386–392.
- Kesch C, Kratochwil C, Mier W, et al. . 68Ga or 18F for prostate cancer imaging? J Nucl Med. 2017;58:687–688.
- Sanchez-Crespo A. Comparison of gallium-68 and fluorine-18 imaging characteristics in positron emission tomography. Appl Radiat Isot. 2013;76:55–62.
- McBride WJ, Sharkey RM, Karacay H, et al. . A novel method of 18F radiolabeling for PET. J Nucl Med. 2009;50:991–998.
- Paulino AC, Johnstone PA. FDG-PET in radiotherapy treatment planning: Pandora’s box? Int J Radiat Oncol Biol Phys. 2004;59:4–5.
- Nestle U, Schaefer-Schuler A, Kremp S, et al. . Target volume definition for 18F-FDG PET-positive lymph nodes in radiotherapy of patients with non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2007;34:453–462.
- Hindorf C, Glatting G, Chiesa C, et al. . EANM dosimetry committee guidelines for bone marrow and whole-body dosimetry. Eur J Nucl Med Mol Imaging. 2010;37:1238–1250.
- Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005;46:1023–1027.
- Andersson M, Johansson L, Eckerman K, et al. . IDAC-Dose 2.1, an internal dosimetry program for diagnostic nuclear medicine based on the ICRP adult reference voxel phantoms. EJNMMI Res. 2017;7:88.
- Menzel HG, Clement C, DeLuca P. ICRP publication 110: realistic reference phantoms—an ICRP/ICRU joint effort. A report of adult reference computational phantoms. Ann ICRP. 2009;39:1–164.
- Bolch WE, Jokisch D, Zankl M, et al. . ICRP publication 133: the ICRP computational framework for internal dose assessment for reference adults—specific absorbed fractions. Ann ICRP. 2016;45:5–73.
- Kratochwil C, Flechsig P, Lindner T, et al. . 68Ga-FAPI PET/CT: tracer uptake in 28 different kinds of cancer. J Nucl Med. 2019;60:801–805.
- Sahiner I, Vural GU. Positron emission tomography/computerized tomography in lung cancer. Quant Imaging Med Surg. 2014;4:195–206.
- Gould MK, Maclean CC, Kuschner WG, et al. . Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis. JAMA. 2001;285:914–924.
- Behzadi A, Ung Y, Lowe V, et al. . The role of positron emission tomography in the management of non-small cell lung cancer. Can J Surg. 2009;52:235–242.
- Fernandes AT, Shen J, Finlay J, et al. . Elective nodal irradiation (ENI) vs. involved field radiotherapy (IFRT) for locally advanced non-small cell lung cancer (NSCLC): a comparative analysis of toxicities and clinical outcomes. Radiother Oncol. 2010;95:178–184.
- Goldstraw P, Ball D, Jett JR, et al. . Non-small-cell lung cancer. Lancet. 2011;378:1727–1740.
- De Ruysscher D, Nestle U, Jeraj R, et al. . PET scans in radiotherapy planning of lung cancer. Lung Cancer. 2012;75:141–145.
- Broderick SR, Patterson GA. Performance of integrated positron emission tomography/computed tomography for mediastinal nodal staging in non-small cell lung carcinoma. Thorac Surg Clin. 2013;23:193–198.
- De Ruysscher D. PET-CT in radiotherapy for lung cancer. Methods Mol Biol. 2011;727:53–58.
- Giesel FL, Heussel CP, Lindner T, et al. . FAPI-PET/CT improves staging in a lung cancer patient with cerebral metastasis. Eur J Nucl Med Mol Imaging. 2019;46:1754–1755.
- Nestle U, Kremp S, Schaefer-Schuler A, et al. . Comparison of different methods for delineation of 18F-FDG PET-positive tissue for target volume definition in radiotherapy of patients with non-small cell lung cancer. J Nucl Med. 2005;46:1342–1348.
- Erdi YE, Mawlawi O, Larson SM, et al. . Segmentation of lung lesion volume by adaptive positron emission tomography image thresholding. Cancer. 1997;80:2505–2509.
- Boellaard R, Krak NC, Hoekstra OS, et al. . Effects of noise, image resolution, and ROI definition on the accuracy of standard uptake values: a simulation study. J Nucl Med. 2004;45:1519–1527.
- Krak NC, Boellaard R, Hoekstra OS, et al. . Effects of ROI definition and reconstruction method on quantitative outcome and applicability in a response monitoring trial. Eur J Nucl Med Mol Imaging. 2005;32:294–301.
- Chen H, Pang Y, Wu J, et al. . Comparison of [68Ga]Ga-DOTA-FAPI-04 and [18F] FDG PET/CT for the diagnosis of primary and metastatic lesions in patients with various types of cancer. Eur J Nucl Med Mol Imaging. 2020;47:1820–1832.
- Luo Y, Pan Q, Zhang W. IgG4-related disease revealed by 68Ga-FAPI and 18F-FDG PET/CT. Eur J Nucl Med Mol Imaging. 2019;46:2625–2626.
- Varasteh Z, Mohanta S, Robu S, et al. . Molecular imaging of fibroblast activity after myocardial infarction using a 68Ga-labeled fibroblast activation protein inhibitor, FAPI-04. J Nucl Med. 2019;60:1743–1749.
- Meyer C, Dahlbom M, Lindner T, et al. . Radiation dosimetry and biodistribution of 68Ga-FAPI-46 PET imaging in cancer patients. J Nucl Med. 2020;61:1171–1177.
- Afshar-Oromieh A, Hetzheim H, Kübler W, et al. . Radiation dosimetry of 68Ga-PSMA-11 (HBED-CC) and preliminary evaluation of optimal imaging timing. Eur J Nucl Med Mol Imaging. 2016;43:1611–1620.
- Sandström M, Velikyan I, Garske-Román U, et al. . Comparative biodistribution and radiation dosimetry of 68Ga-DOTATOC and 68Ga-DOTATATE in patients with neuroendocrine tumors. J Nucl Med. 2013;54:1755–1759.
- Quinn B, Dauer Z, Pandit-Taskar N, Schoder H, Dauer LT. Radiation dosimetry of 18F-FDG PET/CT: incorporating exam-specific parameters in dose estimates. BMC Med Imaging. 2016;16:41.
- Vesselle H, Grierson J, Peterson LM, Muzi M, Mankoff DA, Krohn KA. 18F-fluorothymidine radiation dosimetry in human PET imaging studies. J Nucl Med. 2003;44:1482–1488.
- Pauleit D, Floeth F, Herzog H, et al. . Whole-body distribution and dosimetry of O-(2-[18F]fluoroethyl)-l-tyrosine. Eur J Nucl Med Mol Imaging. 2003;30:519–524.
- Smolarz K, Krause BJ, Graner FP, et al. . (S)-4-(3-18F-fluoropropyl)-l-glutamic acid: an 18F-labeled tumor-specific probe for PET/CT imaging–dosimetry. J Nucl Med. 2013;54:861–866.
- Giesel FL, Hadaschik B, Cardinale J, et al. . F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients. Eur J Nucl Med Mol Imaging. 2017;44:678–688.
- O’Keefe GJ, Saunder TH, Ng S, et al. . Radiation dosimetry of beta-amyloid tracers 11C-PiB and 18F-BAY94-9172. J Nucl Med. 2009;50:309–315.
- Maddahi J, Bengel F, Czernin J, et al. . Dosimetry, biodistribution, and safety of flurpiridaz F18 in healthy subjects undergoing rest and exercise or pharmacological stress PET myocardial perfusion imaging. J Nucl Cardiol. 2019;26:2018–2030.
- DeGrado TR, Reiman RE, Price DT, Wang S, Coleman RE. Pharmacokinetics and radiation dosimetry of 18F-fluorocholine. J Nucl Med. 2002;43:92–96.
- Graham MM, Peterson LM, Link JM, et al. . Fluorine-18-fluoromisonidazole radiation dosimetry in imaging studies. J Nucl Med. 1997;38:1631–1636.
Source: PubMed